Pharmaceutical market research is evolving rapidly with AI 🤖 at the forefront. From improving R&D 🎙 efficiency to revolutionizing drug discovery 💊 and cancer treatment, AI technologies like NLP and machine learning are transforming the industry. Dive into our blog to see how our AI-driven platform offers real-time updates and automated literature reviews, providing unparalleled insights and a competitive edge 👇 https://lnkd.in/gyp8sByp #pharma #pharmaindustry #pharmaceuticalresearch #pharmamarketresearch #marketresearch #AIinLifeSciences #pharmamarket
ngram
Software Development
San Francisco, CA 7,353 followers
Life Sciences Data. Now Connected and Conversable.
About us
Leveraging AI to transform life sciences. We are committed to turning data into actionable insights and ensuring meaningful interactions within healthcare organizations.
- Industry
- Software Development
- Company size
- 11-50 employees
- Headquarters
- San Francisco, CA
- Type
- Privately Held
Locations
-
Primary
San Francisco, CA, US
Employees at ngram
Updates
-
#Oncology data experts, are you keeping your 👀 on this #poll? #pharmaceuticalindustry #pharma #biopharma #biopharmaindustry #pharmamarket #pharmaindustry
This content isn’t available here
Access this content and more in the LinkedIn app
-
📈 Exciting developments in the #biopharma industry! After a slowdown in 2022 and 2023, mergers and acquisitions (M&A) activity is surging in 2024. Here are the key highlights from GlobalData's latest report: 🔄 Biopharma M&A increased by 71% year-over-year in Q1 2024. 💰 Total deal value reached $43.5 billion in Q1 2024. 🌟 Mega M&A deals are expected to positively impact the pharma industry throughout the year. 💼 Novo Holdings made the biggest deal with a $16.5 billion acquisition of Catalent to boost obesity drug manufacturing. 🔬 Gilead Sciences acquired CymaBay Therapeutics for $4.3 billion. 🧬 Antibody-drug conjugates (ADCs) are attracting high levels of investment. 🤝 Smaller acquisitions include Johnson & Johnson's $2 billion purchase of Ambrx Biopharma and AstraZeneca's $2 billion acquisition of Fusion Pharmaceuticals. 🧪 Oncology remains the leading therapeutic area for M&A, with a total deal value of $29 billion. 🚀 Immunology-focused deals saw a 314% increase in deal value compared to last year. 🔮 The report anticipates more M&A activity throughout 2024, potentially accelerating R&D and innovative drug launches. Business analysts at GlobalData Plc believe that the recent upturn in #biopharmaceutical #M&A signals a return in dealmaking confidence. 🌟 #biopharmaindustry #pharmaindustry #pharma
-
With the major public #BioPharma companies having released their first-quarter results for 2024, let's examine the world's top-selling medicines 💊 #PharmaData #BioPharmaData #BioPharmaMarket #PharmaIndustry
-
This therapy area is set to dominate sales in 2024 📈 #pharma #pharmaindustry #pharmatrends #biopharma
This content isn’t available here
Access this content and more in the LinkedIn app
-
👉🏽 World Vitiligo Day: 25 June 🔍 #Vitiligo is a skin condition causing patches of pigment loss. It can affect any body part, including hair and mouth. The condition occurs when melanin-producing cells die or malfunction. While not life-threatening, vitiligo can be more noticeable on darker skin and may cause emotional distress. 💉 The current treatments for vitiligo include a variety of approaches aimed at managing the disease by halting its progression, stabilizing depigmented lesions, and encouraging repigmentation. These include #pharmalogicaltreatments, #phototherapy, #surgicaltreatments, and #depigmentation. These treatments, used alone or in combination, have exhibited varying degrees of success in managing vitiligo, with many being safe and effective. ✅ The only FDA-approved cream for treating vitiligo pigmentation is Opzelura (ruxolitinib). It is a topical Janus kinase (JAK) inhibitor approved for the treatment of nonsegmental vitiligo in patients aged 12 and older. 🔬 If you want to dig deeper into Vitiligo, visit: ngram.com/chat ngram.com/trials #autoimmunedisease #pharmaindustry #pharma #biotechnology #biopharma #worldvitiligoday
-
The pharmaceutical industry is witnessing a surge in the adoption of artificial intelligence (AI) solutions. A new report by Research2Guidance provides a comprehensive analysis of AI-focused collaborations, partnerships, investments, and acquisitions among 10 major pharmaceutical companies since 2021. Key Highlights: 🫱🏽🫲🏼 139 AI collaborations have been closed by 10 big pharma companies in just the last three years, a clear sign of their drive for innovation through AI partnerships. 🚀 AstraZeneca leads the pack as the most active pharma company in AI collaborations, followed closely by Janssen, BMS, Bayer, and Sanofi. 💊 43% of the AI collaborations focused on drug discovery and development, while 32% targeted diagnostics and monitoring, leveraging advanced AI capabilities. 🔬 Partners like PathAI, Lunit, Owkin, Tempus, and Google emerge as preferred choices for pharma giants in deploying AI solutions for drug discovery, diagnostics, and clinical studies. ❎ Domains like knowledge management, supply chain optimization, marketing, and regulatory affairs remain relatively unexplored for AI collaborations, indicating potential areas for future partnerships. 🤖 Big Tech players – Google, Microsoft, IBM, and Amazon – are actively involved in multiple collaborations to integrate AI into various pharma operations. As the pharmaceutical industry navigates this AI-driven trajectory, a strategic approach to AI partnerships becomes crucial. Prioritizing use cases, selecting partners, and building collaborations are key to harnessing the full potential of AI technologies in the pharma domain. #AI #ArtificalIntelligence #Pharma For the full report, please check the comments. 👇🏽
-
🚨 A cool new update to our Clinical Trials database at ngram.com/trials You can now receive ⏳ timely, 🤖 AI-driven updates on Clinical Trials that interest you, mailed directly to your inbox! 1️⃣ Visit ngram.com/trials 2️⃣ Explore our Clinical Trials database (500K+ trials) 3️⃣ Subscribe to our alerts to stay updated on the trials that interest you! #AI #GenerativeAI #ClinicalResearch #competitiveintelligence #ClinicalTrials
-
✅ In 2023, the FDA approved the second-highest number of drugs, after 59 approvals in 2018. The drugs were analyzed exclusively on the basis of their chemical structure 🧬 and were classified as biologics (antibodies, proteins/enzymes); TIDES (peptide and oligonucleotides); combined drugs; pegylated drugs; natural products; nitrogen aromatic heterocycles; fluorine-containing molecules; and other small molecules. 👉🏽 Continue to mine pharma data with ngram.com/chat #pharmadata #pharma #biopharma #competitiveintelligence
This content isn’t available here
Access this content and more in the LinkedIn app
-
If you're a #pharma professional and not using our AI-powered solutions, you're missing out! Take a minute to check them out 👇🏽 1️⃣ nGram chat: ngram.com/chat 2️⃣ nGram alerts: https://lnkd.in/gpU5HMBf 3️⃣ nGram Clinical Trials database: ngram.com/trials #competitiveintelligence #pharmacompetitiveintelligence #AIinLifeSciences